0541 GMT - CSPC Pharmaceutical Group may benefit from higher success odds of its 'SYS6010' antibody-drug conjugate, China Galaxy International's Lily Wang says in a research report. SYS6010 has demonstrated tolerable safety and promising efficacy in both Epidermal Growth Factor Receptor-mutant and EGFR wild-type non-small cell lung cancer, the analyst notes. Also, management highlighted its business development performance in 2025 could exceed its previous guidance of 2-3 more deals, including at least three out-licensing deals worth over US$5 billion each, the analyst adds. The brokerage raises the stock's target price to HK$10.04 from HK$7.43 with an unchanged add rating. Shares are 6.2% lower at HK$7.60. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
June 02, 2025 01:41 ET (05:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。